Compare AJANTA PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. REDDYS LAB AJANTA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 21.8 21.5 101.2% View Chart
P/BV x 3.8 3.2 119.2% View Chart
Dividend Yield % 0.9 0.7 125.1%  

Financials

 AJANTA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DR. REDDYS LAB
Mar-19
AJANTA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,4222,875 49.5%   
Low Rs8981,888 47.5%   
Sales per share (Unadj.) Rs233.5930.2 25.1%  
Earnings per share (Unadj.) Rs44.0117.4 37.4%  
Cash flow per share (Unadj.) Rs52.2185.8 28.1%  
Dividends per share (Unadj.) Rs9.0020.00 45.0%  
Dividend yield (eoy) %0.80.8 92.4%  
Book value per share (Unadj.) Rs255.1844.4 30.2%  
Shares outstanding (eoy) m88.02166.07 53.0%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.6 194.0%   
Avg P/E ratio x26.420.3 130.1%  
P/CF ratio (eoy) x22.212.8 173.4%  
Price / Book Value ratio x4.52.8 161.2%  
Dividend payout %20.517.0 120.2%   
Avg Mkt Cap Rs m102,081395,496 25.8%   
No. of employees `0006.822.0 31.0%   
Total wages/salary Rs m4,30733,562 12.8%   
Avg. sales/employee Rs Th3,022.67,032.8 43.0%   
Avg. wages/employee Rs Th633.41,527.9 41.5%   
Avg. net profit/employee Rs Th569.1887.7 64.1%   
INCOME DATA
Net Sales Rs m20,554154,482 13.3%  
Other income Rs m2113,375 6.2%   
Total revenues Rs m20,765157,857 13.2%   
Gross profit Rs m5,66431,782 17.8%  
Depreciation Rs m72111,348 6.4%   
Interest Rs m12889 1.3%   
Profit before tax Rs m5,14322,920 22.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2733,858 33.0%   
Profit after tax Rs m3,87019,500 19.8%  
Gross profit margin %27.620.6 134.0%  
Effective tax rate %24.816.8 147.1%   
Net profit margin %18.812.6 149.2%  
BALANCE SHEET DATA
Current assets Rs m11,812111,101 10.6%   
Current liabilities Rs m3,77658,973 6.4%   
Net working cap to sales %39.133.7 115.9%  
Current ratio x3.11.9 166.0%  
Inventory Days Days7779 97.5%  
Debtors Days Days8294 86.6%  
Net fixed assets Rs m14,398101,245 14.2%   
Share capital Rs m175830 21.1%   
"Free" reserves Rs m22,277139,406 16.0%   
Net worth Rs m22,452140,236 16.0%   
Long term debt Rs m722,000 0.0%   
Total assets Rs m26,962224,656 12.0%  
Interest coverage x444.326.8 1,659.1%   
Debt to equity ratio x00.2 0.2%  
Sales to assets ratio x0.80.7 110.9%   
Return on assets %14.49.1 158.6%  
Return on equity %17.213.9 123.9%  
Return on capital %23.014.9 153.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68288,673 12.0%   
Fx outflow Rs m2,10219,104 11.0%   
Net fx Rs m8,58069,569 12.3%   
CASH FLOW
From Operations Rs m3,74828,704 13.1%  
From Investments Rs m-2,228-7,727 28.8%  
From Financial Activity Rs m-1,475-21,326 6.9%  
Net Cashflow Rs m45-314 -14.4%  

Share Holding

Indian Promoters % 73.8 25.5 289.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.4 28.7%  
FIIs % 7.6 35.3 21.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.0 15.3 111.1%  
Shareholders   20,968 75,885 27.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 17, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS